<DOC>
	<DOCNO>NCT00716833</DOCNO>
	<brief_summary>This randomise placebo control double-blinded bicentre study ( phase III ) design evaluate preemptive postoperative analgetic impact etoricoxibe open abdominal thoracic surgery . Etoricoxib selectively inhibit isoform 2 cyclo-oxigenase enzyme ( COX-2 ) . Therefore 120 patient ( ASA-risk 1-2 ) upcoming abdominal thoracic surgery include study . Patients randomly allocate either preemptive postoperative Etoricoxibe group . These two group divide two arm . Preemptive group patient get Etoricoxibe either twice ( surgery ) single preoperative dose . Postoperative group patient get placebo surgery either drug application placebo surgery ( call 2x2 factorial study design ) . Cumulative use morphine assess within first 48 hour surgery primary trial outcome indicate analgesic potency Etoricoxibe . In addition , change patient level sensibilisation measure help quantitative sensory testing ( standardised procedure ) surgery ( secondary outcome ) . In addition pharmacogenetic test provide information genetic aberration ( call polymorphism ) patient enzymes compare individual reaction regard Etoricoxibe . The result give hint analgesic impact etoricoxibe acute postoperative pain . There finding preemptive analgesia nerval process . All could lead improvement postoperative pain relief administrate preemptively COX-2 selective inhibitor surgery .</brief_summary>
	<brief_title>Etoricoxibe - Preemptive Postoperative Analgesia Abdominal Thoracic Surgery</brief_title>
	<detailed_description>Etoricoxib ( brand name Arcoxia worldwide ; also Algix Tauxib Italy ) new COX-2 selective inhibitor ( approx . 106.0 time selective COX-2 inhibition COX-1 ) . Doses 120 mg/day acute pain . Current therapeutic indication : treatment rheumatoid arthritis , osteoarthritis , ankylose spondylitis , chronic low back pain , acute pain gout . Note approve indication differ country . Like COX-2 selective inhibitor , Etoricoxib selectively inhibit isoform 2 cyclo-oxigenase enzyme ( COX-2 ) . This reduce generation prostaglandin ( PGs ) arachidonic acid . Among different function exert PGs , role inflammation cascade highlight . COX-2 selective inhibitor ( aka `` COXIB '' ) show less marked activity type 1 cycloxigenase compare traditional non-steroidal anti-inflammatory drug ( NSAID ) . This reduced activity cause reduce gastrointestinal toxicity . Quantitative sensory test ( QST ) techniques employ measure intensity stimulus need produce specific sensory perception . They use evaluate sensory detection threshold sensory response supra-threshold stimulation . The common physical stimulus ( ) touch-pressure , ( ii ) vibration , ( iii ) coolness , warmth , cold pain , heat pain . In QST , subject must able comprehend ask test , alert take mind-altering medication , bias certain test outcome .</detailed_description>
	<criteria>Programmed abdominal thoracic surgery Patients &gt; 18 yr Patients aware German language Participation voluntary ASArisk class 12 ( American Society Anesthesiologists guideline ) Severe cardiac , pulmonary , renal neurologic disease ASA risk III IV Insulin dependent Diabetes mellitus Polyneuropathy Chronic pain Use analgesic drug Ulcus duodeni Ulcus ventriculus Time intestinal bleeding Allergy reaction towards coxibes coxibelike drug Pregnancy lactation Severe hepatic disease ( Albumin &lt; 25 g/l ChildPughScore â‰¥ 10 ) Children Teenager &lt; 16 year Chronic intestinal inflammation Heart failure ( NYHA II IV ) Inbalancend arterial hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>pain</keyword>
	<keyword>coxibe</keyword>
	<keyword>preemptive</keyword>
	<keyword>abdominothoracic</keyword>
	<keyword>sensibilisation</keyword>
	<keyword>Analgesia</keyword>
</DOC>